154 related articles for article (PubMed ID: 18473784)
1. The compound 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid inhibits HIV-1 replication by targeting the enzyme reverse transcriptase.
Souza TM; Cirne-Santos CC; Rodrigues DQ; Abreu CM; Tanuri A; Ferreira VF; Marques IP; de Souza MC; Fontes CF; Frugulhetti IC; Bou-Habib DC
Curr HIV Res; 2008 May; 6(3):209-17. PubMed ID: 18473784
[TBL] [Abstract][Full Text] [Related]
2. Characterization of HIV-1 enzyme reverse transcriptase inhibition by the compound 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid through kinetic and in silico studies.
Souza TM; Rodrigues DQ; Ferreira VF; Marques IP; da Costa Santos F; Cunha AC; de Souza MC; de Palmer Paixão Frugulhetti IC; Bou-Habib DC; Fontes CF
Curr HIV Res; 2009 May; 7(3):327-35. PubMed ID: 19442130
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HSV-1 replication and HSV DNA polymerase by the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid and its aglycone.
Souza TM; De Souza MC; Ferreira VF; Canuto CV; Marques IP; Fontes CF; Frugulhetti IC
Antiviral Res; 2008 Jan; 77(1):20-7. PubMed ID: 17931712
[TBL] [Abstract][Full Text] [Related]
4. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
[TBL] [Abstract][Full Text] [Related]
5. A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.
Urano E; Miyauchi K; Kojima Y; Hamatake M; Ablan SD; Fudo S; Freed EO; Hoshino T; Komano J
ChemMedChem; 2016 Oct; 11(20):2320-2326. PubMed ID: 27634404
[TBL] [Abstract][Full Text] [Related]
6. The dolabellane diterpene Dolabelladienetriol is a typical noncompetitive inhibitor of HIV-1 reverse transcriptase enzyme.
Cirne-Santos CC; Souza TM; Teixeira VL; Fontes CF; Rebello MA; Castello-Branco LR; Abreu CM; Tanuri A; Frugulhetti IC; Bou-Habib DC
Antiviral Res; 2008 Jan; 77(1):64-71. PubMed ID: 17888523
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
Okamoto M; Okamoto T; Baba M
Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
[TBL] [Abstract][Full Text] [Related]
9. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
10. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
11. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
[TBL] [Abstract][Full Text] [Related]
13. PMTI, a broadly active unusual single-stranded polyribonucleotide, inhibits human immunodeficiency virus replication by multiple mechanisms.
Buckheit RW; Lackman-Smith C; Snow MJ; Halliday SM; White EL; Ross LJ; Agrawal VK; Broom AD
Antivir Chem Chemother; 1999 Jan; 10(1):23-32. PubMed ID: 10079876
[TBL] [Abstract][Full Text] [Related]
14. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
Sluis-Cremer N; Tachedjian G
Virus Res; 2008 Jun; 134(1-2):147-56. PubMed ID: 18372072
[TBL] [Abstract][Full Text] [Related]
17. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).
Joshi P; Prasad VR
J Virol; 2002 Jul; 76(13):6545-57. PubMed ID: 12050367
[TBL] [Abstract][Full Text] [Related]
19. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
20. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6.
Corona A; Meleddu R; Esposito F; Distinto S; Bianco G; Masaoka T; Maccioni E; Menéndez-Arias L; Alcaro S; Le Grice SF; Tramontano E
PLoS One; 2016; 11(1):e0147225. PubMed ID: 26800261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
